.jpg "Eyegate (NASDAQ: EYEG)")
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Eyegate (NASDAQ: EYEG), with a price target of $3. The company’s shares closed yesterday at $0.48.
According to TipRanks.com, Selvaraju is a 4-star analyst with an average return of 5.7% and a 48.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Synergy Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Eyegate with a $3 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $1.38 and a one-year low of $0.29. Currently, Eyegate has an average volume of 437.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
EyeGate Pharma is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes EGP-437 and Ocular Bandage Gel (OBG).
